Biotron Limited
A.B.N. 60 086 399 144

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

6 October 2015

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000 (10 pages by email)

Dear Madam

PRESENTATION TO INVESTORS

I attach a PowerPoint presentation as presented by Biotron Limited's Managing Director, Dr Michelle Miller, to investors.

Yours sincerely

Peter J. Nightingale
Company Secretary

pjn8235

BIOTRON LIMITED
(ASX:BIT)

Australia Biotech Invest

October 2015

Michelle Miller
Managing Director
+61 (0) 412 313 329
mmiller@biotron.com.au

Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

BIT225 Snapshot

- First in class drug and new drug target for treatment of HIV and Hepatitis C virus (HCV)
- Seven clinical trials completed; one in progress (HCV G3 interim data reported; G1 due 1Q16)
- Demonstrated clinical activity against HCV G1 and G3
- Independently shown to have HCV pan-genotype activity *in vitro*
- Efficiently inhibits HIV replication in monocyte/macrophage reservoir cells *in vitro* and *in vivo*
- Patent position over compound and its uses
- Compound is relatively easy to make and formulate; very stable at room temperature – important for supply chains
- Significantly undervalued compared to other HCV drugs = potential for considerable upside

Financial Information

Key Financial Metrics

Ticker Code	ASX: BIT
Share Price (5 Oct 2015)	A $0.54
Market cap	A $15 million
12 Month Trading Range	A $0.041 – 0.183
Shares Outstanding	313 million
Options (BITO)	50.7 million $0.12 expiry 30/09/16
Cash Position (06/2015)	A $6.5 million

Board

Michael Hoy	Non-executive Chairman
Michelle Miller	Managing Director
Susan Pond	Non-executive Director
Rob Thomas	Non-executive Director
Denis Wade	Non-executive Director

12 Month Share Price Performance

BIT225 - Proven Activity Against HCV

- Independently shown to work against all HCV genotypes *in vitro*
- Over 200 patients and healthy volunteers dosed with BIT225 to date
- BIT225 has consistently shown positive data:
    - HCV G1 (BIT225-005) – 100% receiving 400mg (28 days in combination with 48 weeks IFN/RBV) were **virus-free** at 48 weeks
    - Co-infected HIV/HCV GT3 (BIT225-006) – 100% completing course of 300mg (28 days in combination with 48 weeks IFN/RBV) were HCV-free 12 weeks post-treatment (SVR12) i.e. **cured of HCV infection**
- Trials of BIT225 to date in combination with IFN/RBV as cannot test HCV drugs on their own
- BIT225 positioned to fill potential gaps left by other HCV drugs – **only one of its class**

BIT225 – First of a New Class of HCV Drugs



- ✓ Novel, oral, small molecule compound
- ✓ Only one of its class (p7 inhibitor) in clinical trials
- ✓ Inhibits viral assembly and infectivity
- ✓ Pan-genotype activity:
  - ✓ Active *in vitro* against all main genotypes
  - ✓ Clinically active against hard-to-treat HCV Gen 1 (1a and 1b) and Gen 3
- ✓ Also active against HIV hiding in reservoir cells

Biotron

Positioning of BIT225 for Hepatitis C

- New HCV drug combinations not optimal
  - Cost of new treatments is excessive:
    - Sovaldi US$84,000 for 12 weeks; Harvoni US$94,500 for 12 weeks
  - Lengthy treatment – 12 weeks or more
  - Not pan-genotypic – **BIT225 is pan-genotypic *in vitro***
  - Not as effective against HCV G3 – **BIT225 has good activity against HCV G3 (and G1)**
  - More treatment failures than anticipated **– need for new classes of drugs like BIT225**
  - **Resistance may become more of an issue with new HCV classes – need for new classes as for HIV**

What Interim Data from BIT225-008 Means

- Interim data from BIT225-008 (3 month dosing study in HCV gen 1 and gen 3):
  - We now have safety data with the new capsule formulation out to 12 week dosing
    - i.e. sufficient for dosing studies with new HCV drugs
    - **Prime aim of the trial**
  - The gen 3 cohort responded better than expected to IFN/RBV
    - Rates depend on age, gender, liver damage, genetics, etc
    - SVR12 rates excellent in BIT225/IFN/RBV and placebo/IFN/RBV arms (88% and 90%)
  - Withdrawals higher than expected but retrospective analysis shows majority NOT due to BIT225
  - BIT225 did not fail in this study
    - **BIT225 is still a very promising new antiviral drug for HIV and HCV infections**

Outlook for 2015/16

- Complete BIT225-008 HCV trial
  - HCV Gen 1 due 1Q16
- Investigational New Drug application
  - Complete IND-related activities required by the FDA
    - Modeling of pharmacokinetic data from all trials to determine optimal BIT225 dose and frequency in IND trials; Exposure/AE analysis (**008 trial data is KEY**)
    - Drug-drug interaction studies (*in vitro* and *in vivo*)
  - File IND application 1Q16
- Phase 2 HIV trial to commence 1H16
- Expand earlier stage drug programs e.g. Dengue virus
- Continue commercialisation activities aimed at attracting partners
- Continue to promote company to local and international investment community